Key result
Integrated cardiorenal management emphasizes combined SGLT2 inhibitor, GLP-1 receptor agonist, and finerenone therapy.
Why the study?
The therapeutic management of cardiorenal syndrome has evolved with new pharmacological agents targeting multiple pathophysiological axes, necessitating an updated integrated treatment paradigm.
The management of cardiorenal syndrome is shifting toward an integrated cardiovascular-renal-metabolic paradigm using personalized quadruple therapy to optimize patient outcomes.
The therapeutic landscape of cardiorenal syndrome (CRS) has evolved significantly, transitioning from historical cornerstones like angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) to modern neurohormonal modulation with angiotensin receptor–neprilysin inhibitors (ARNIs). This second part of this narrative review analyzes the pivotal pharmacological roles of sodium–glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and finerenone, which target the hemodynamic, metabolic, and inflammatory–fibrotic axes, respectively, alongside the essential utility of novel potassium binders. Ultimately, the management of CRS is shifting toward an integrated cardiovascular–renal–metabolic paradigm, where the future lies in a personalized, biomarker-guided “quadruple cardiorenal therapy” that moves beyond a single-organ focus to optimize patient outcomes.
No takes yet. Share an insight, caveat, or question.
Mauriello et al. (2026) conducted a review in Cardiorenal syndrome. SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone was evaluated. Modern pharmacological management of cardiorenal syndrome emphasizes an integrated cardiovascular-renal-metabolic paradigm incorporating SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: